{
    "clinical_study": {
        "@rank": "92616", 
        "brief_summary": {
            "textblock": "To evaluate and compare the safety, tolerability, and effectiveness of long-term biweekly\n      administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in\n      patients who have had multiple episodes of AIDS associated Pneumocystis carinii pneumonia\n      (PCP)."
        }, 
        "brief_title": "A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  Recovered from their most recent episode of Pneumocystis carinii pneumonia (PCP).\n             Patients must be at least 2 weeks status post therapy for acute PCP.\n\n          -  Adequate pulmonary function (vital capacity = or > 65 percent of predicted; forced\n             expiratory volume, 1 s = or > 55 percent of total FEV; and corrected pulmonary\n             diffusion capacity > 50 percent of predicted).\n\n          -  Patients must be free of acute medical problems.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  AIDS-defining opportunistic infection prior to entry such as toxoplasmosis and\n             cryptococcosis.\n\n          -  Pulmonary Kaposi's sarcoma.\n\n          -  Asthma poorly controlled by medication.\n\n          -  Receiving active therapy for tuberculosis.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Active therapy for tuberculosis.\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection at time of study\n             entry.\n\n          -  AIDS-defining opportunistic infection prior to study entry such as toxoplasmosis and\n             cryptococcosis.\n\n          -  Pulmonary Kaposi's sarcoma.\n\n          -  Unwilling to sign informed consent.\n\n          -  Asthma poorly controlled by medication.\n\n          -  Unwilling to cooperate with study procedures.\n\n          -  Receiving active therapy for tuberculosis.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Antiretrovirals (other than zidovudine (AZT)).\n\n          -  Immunomodulating agents.\n\n          -  Corticosteroids.\n\n        Prior Treatment:\n\n        Excluded within 7 days of study entry:\n\n          -  Transfusion.\n\n          -  Patient cannot be transfusion dependent (requiring blood transfusion more than once\n             per month).\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002055", 
            "org_study_id": "022D", 
            "secondary_id": "88-7"
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentamidine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Dose-Response Relationship, Drug", 
            "Aerosols", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20422"
                    }, 
                    "name": "Veterans Administration Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - West Campus"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "citation": "Lavelle J, Murphy R, Harding P, Pierce P. Aerosolized pentamidine prophylaxis following Pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1990 Jun 20-23;6(2):374 (abstract no 2083)"
            }, 
            {
                "PMID": "2012082", 
                "citation": "Murphy RL, Lavelle JP, Allan JD, Gordin FM, Dupliss R, Boswell SL, Waskin HA, Davies SF, Graziano FM, Saag MS, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991 Apr;90(4):418-26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002055"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fisons", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1990"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess - West Campus": "42.358 -71.06", 
        "Georgetown Univ": "38.895 -77.036", 
        "Northwestern Univ Med School": "41.878 -87.63", 
        "Veterans Administration Med Ctr": "38.895 -77.036"
    }
}